Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?
Two bills aim to close gaps and ensure equitable access by requiring private health insurance coverage of FDA-approved ...
Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...
Lars Lannfelt, Pär Gellerfors, and Gunilla Osswald awarded Uppsala Universityâ€TMs Innovation and Entrepreneurship Prize ...
Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...
Health is pioneering a new model of cognitive care, designed to increase access, improve outcomes, and support both patients and healthcare ...
Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...
Despite reporting positive Phase II results for its lead candidate last year, Vaccinex will soon no longer be a publicly ...
Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...
US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...
Layoffs are a fact of life in the pharma and biotech industries with companies frequently adjusting headcount as their priorities shift. But the steady stream of cuts grew stronger last year as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback